Drawdowns & Recovery
COHANCEAll-Time High & Drawdowns
Cohance Lifesciences Ltd.
COHANCE last closed at ₹450, 66.9% below its all-time high of ₹1,360. The deepest fall in its record was -77.0%, and it spent 22 months below that peak.
- All-time high
- ₹1,360
- Latest close
- ₹450
- Below the high
- 66.9%
- Worst fall on record
- -77.0%
All-Time High
COHANCE all-time high price
The highest price COHANCE has ever traded at is ₹1,360, first reached on 2 December 2024. It last closed at ₹450, which is 66.9% below it.
- All-time high
- ₹1,360
- Reached
- 2 December 2024
- Distance today
- -66.9%
Measured on intraday highs adjusted for stock splits but not for dividends — the basis on which prices are quoted, so this is directly comparable with the price on your screen. It is deliberately a different measurement from the drawdown below, which is a total-return figure.
Trailing Year
COHANCE 52-week high and low
Over the last twelve months COHANCE has traded between ₹267 and ₹1,039, and sits 56.7% below the top of that range.
The window is the twelve months ending 2026-08-31. Figures refresh when our data pipeline runs, not continuously — this is a research record, not a live quote.
The Worst Fall
The biggest fall COHANCE has ever had
The deepest drawdown in Cohance Lifesciences Ltd.'s record is -77.0% — from a peak in October 2024 to a low in March 2026. That is the loss an investor holding throughout would have been looking at on paper, with dividends counted as reinvested.
- Peak
- October 2024
- Trough
- March 2026
- Fall
- -77.0%
- Recovered
- Not yet
COHANCE has not yet closed a month above that peak. The record is still open, which is a different statement from a recovery that took a long time.
Measured on month-end values, so a fall that went deeper inside a month and came back before month end is not captured — a real intra-month low was at least this bad and possibly worse. Dividends are treated as reinvested, which makes this shallower than the fall in the quoted price.
Recovery
How long COHANCE took to recover
Depth is only half of a drawdown. The part that decides whether someone holds on is how long they spend waiting to get back to where they were.
The worst stretch
COHANCE spent 1 year and 10 months below its previous peak during the -77.0% fall, and has not cleared it yet.
Where it stands now
On a total-return basis COHANCE sits 65.8% below its best month, which was October 2024 — 1 year and 10 months ago.
These figures are total return — the peak is the high point of a holding whose dividends were reinvested, which is not the same as the highest quoted price. The quoted-price figures are in the all-time-high section above, and the two will differ on any company that pays a dividend.
How This Is Calculated
Reading these figures properly
Two different bases
The all-time high and 52-week range are quoted prices — split-adjusted, dividends excluded. The drawdown and recovery figures are total return, with dividends reinvested. On a dividend payer they will not agree, and that difference is the dividends rather than an error.
Month-end drawdowns
The fall and recovery are measured on month-end values, so a deeper low inside a month that recovered before the month closed is not captured. The real worst moment was at least this bad.
Not a live quote
Figures refresh when our data pipeline runs, not tick by tick. This is a research record of what has happened, and it is not intended for trading decisions.
Measured on data to 2026-08-31, from 2020-03-01. Full definitions are on our methodology page.
HELP CENTER
COHANCE all-time high and drawdowns — common questions
Everything you need to know about this page and the data presented.
What is the all-time high of COHANCE?+
₹1,360, first reached on 2 December 2024. Cohance Lifesciences Ltd. last closed at ₹450, which is 66.9% below it. This is an intraday high adjusted for stock splits but not for dividends, so it is directly comparable with the price quoted today. Figures update when our data pipeline runs rather than continuously.
How far is COHANCE from its all-time high?+
66.9% below it. Recovering that would take a gain of about 202.3% from here — the asymmetry that makes falls harder to undo than they look, because a 50% fall needs a 100% gain to reverse.
What is the 52-week high and low of COHANCE?+
Over the last twelve months Cohance Lifesciences Ltd. traded between ₹267 and ₹1,039, and last closed at ₹450. Both figures are intraday — the highest and lowest prices actually printed in the window, not the highest and lowest closes.
What is the biggest fall COHANCE has ever had?+
-77.0%, from a peak in October 2024 to a low in March 2026. That is measured on total return, so dividends are counted as reinvested and the fall in the quoted price was deeper still. It is also measured on month-end values, which means an intra-month low that recovered before the month closed is not captured — the real worst moment was at least this bad.
How long did COHANCE take to recover from its worst fall?+
It has not recovered yet. Cohance Lifesciences Ltd. fell -77.0% from its October 2024 peak and has not closed a month above that level since. An open drawdown is a different statement from a long recovery — it may still be either.
Why does this page show two different all-time highs?+
Because they measure different things and both are correct. The ₹1,360 figure is a price — the highest COHANCE ever traded at, on the same basis prices are quoted today. The drawdown section instead tracks the value of a holding whose dividends were reinvested, and its peak is the high point of that holding rather than of the price. On a company that pays dividends the two always differ, and using the second one to answer "what is the all-time high" would understate it.
Is COHANCE a good buy after this fall?+
That is not a question this page answers, and we do not make recommendations. What it can tell you is exactly how far Cohance Lifesciences Ltd. has fallen from its high, how deep its worst fall was, and how long the recovery took — the historical context most price pages leave out. A stock that recovered from every previous fall may not recover from this one, and a large fall is not by itself evidence of value. ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser.
Explore Further
More on Cohance Lifesciences Ltd.
COHANCE rolling returns
Every holding period on record — the best, the worst and the median.
COHANCE SIP returns
What a monthly investment through those falls would have produced.
COHANCE overview
Price history, wealth journey and how it compares with the index.
Stocks furthest below their highs
The whole universe ranked by distance from the all-time high.
ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser. Everything on this page is a record of what historical prices did, not a projection and not a recommendation. A large fall is not by itself evidence of value. Past performance does not guarantee future returns. See our methodology and disclaimer.